{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:39:15Z","timestamp":1782387555680,"version":"3.54.5"},"reference-count":53,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ratchadapiseksompotch Fund Chulalongkorn University"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Policy and Practice"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/20523211.2025.2520861","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:54:32Z","timestamp":1751450072000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["A scoping review of authorisation pathway for COVID\n                    <b>-<\/b>\n                    19 vaccines among selected countries"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5819-0751","authenticated-orcid":false,"given":"Supapitch","family":"Suphap","sequence":"first","affiliation":[{"name":"Medicines Regulation Division, Thailand Food and Drug Administration, Ministry of Public Health","place":["Nonthaburi, Thailand"]},{"name":"Chulalongkorn University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-7726","authenticated-orcid":false,"given":"Parnnaphat","family":"Luksameesate","sequence":"additional","affiliation":[{"name":"Chulalongkorn University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8919-0063","authenticated-orcid":false,"given":"Osot","family":"Nerapusee","sequence":"additional","affiliation":[{"name":"Eastern Asia University","place":["Pathumthani, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0203","authenticated-orcid":false,"given":"Puree","family":"Anantachoti","sequence":"additional","affiliation":[{"name":"Chulalongkorn University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-021-00400-0"},{"key":"e_1_3_5_3_1","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios September 17 2020. Vaccines. AEMP. Retrieved December 31 2022 from https:\/\/www.aemps.gob.es\/medicamentos-de-uso-humano\/medicamentos-biologicos\/vacunas\/."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11111-1"},{"key":"e_1_3_5_5_1","unstructured":"Bahagian Regulatori Farmasi Negara (NPRA). (2022). Guidance and requirements on conditional registration for pharmaceutical products during disaster. https:\/\/npra.gov.my\/easyarticles\/images\/users\/1051\/GUIDANCE-AND-REQUIREMENTS-ON-CONDITIONAL-REGISTRATION-OF-PHARMACEUTICAL-PRODUCTS-DURING-DISASTER.pdf"},{"key":"e_1_3_5_6_1","unstructured":"Central Drugs Standard Control Organisation (CDSCO). (2021). Guidance for approval of COVID-19 vaccines in India. 15 April 2021."},{"key":"e_1_3_5_7_1","unstructured":"Central Drugs Standard Control Organisation (CDSCO). (2022 4 Oct 2022). COVID-19 vaccines approved in the country. https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=OTA4MQ=="},{"key":"e_1_3_5_8_1","unstructured":"Centre for Innovation in Regulatory Science (2020) R&D briefing 75. (2020). Emergency Use Pathways (EUPs): applying regulatory flexibility in the age of COVID-19."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.03.049"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_3640_20"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jlb\/lsaa083"},{"key":"e_1_3_5_12_1","unstructured":"European Medicine Agency. (2023). Votrient EMA. Retrieved August 10 2023 from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/votrient"},{"key":"e_1_3_5_13_1","unstructured":"European Medicine Agency (EMA). (2022). Questions and answers on labelling flexibilities for COVID19 vaccines. https:\/\/www.ema.europa.eu\/en\/documents\/other\/questions-answers-labelling-flexibilities-covid-19-vaccines_en.pdf"},{"key":"e_1_3_5_14_1","unstructured":"European Medicine Agency (EMA). (n.d.). COVID-19 vaccines. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/covid-19-vaccines"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114093"},{"key":"e_1_3_5_16_1","unstructured":"Food and Drug Administation Philippines. (2020). FDA circular No. 2020-036 || guidelines on the issuance of emergency use authorization for drugs and vaccines for COVID-19. https:\/\/www.fda.gov.ph\/fda-circular-no-2020-036-guidelines-on-the-issuance-of-emergency-use-authorization-for-drugs-and-vaccines-for-covid-19\/"},{"key":"e_1_3_5_17_1","unstructured":"Food and Drug Administration Philippines. (2022). Emergency use authorization. FDA. Retrieved December 31 2022 from https:\/\/www.fda.gov.ph\/list-of-fda-issued-emergency-use-authorization\/"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-022-00480-3"},{"key":"e_1_3_5_19_1","unstructured":"Govenment of Canada. (2020 16 November). Information and application requirements for drugs authorized under the Interim order: Guidance document. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/interim-order-import-sale-advertising-drugs\/guidance.html#a21"},{"key":"e_1_3_5_20_1","unstructured":"Government of Canada. (2020 12 March). Access consortium statement on COVID-19 vaccines evidence. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/engaging-international-partners\/access-statement-vaccine-evidence.html"},{"key":"e_1_3_5_21_1","unstructured":"Government of the United Kingdom. (2020). Decision regulatory approval of Pfizer\/BioNTech vaccine for COVID-19 https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19"},{"key":"e_1_3_5_22_1","unstructured":"Health Singapore Authority. (2021a). Pandemic Special Access Route (PSAR) for supply of emergency therapeutic products. HSA. Retrieved December 2022 from https:\/\/www.hsa.gov.sg\/therapeutic-products\/register\/special-access-routes\/psar-emergency-therapeutic-product"},{"key":"e_1_3_5_23_1","unstructured":"Health Singapore Authority. (2021b). Special Access Routes (SAR). HSA. Retrieved December 31 2022 from https:\/\/www.hsa.gov.sg\/therapeutic-products\/register\/special-access-routes\/SAR-covid19"},{"key":"e_1_3_5_24_1","unstructured":"International Coalition of Medicines Regulatory Authorities. (2022). COVID-19. ICMRA. Retrieved December 30 2022 from https:\/\/icmra.info\/drupal\/"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-021-00512-4"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.722872"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14531"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4759"},{"key":"e_1_3_5_29_1","unstructured":"Medicines & Healthcare products Regulatory Agency (MHRA). (2020). Guidance conditional marketing authorisations exceptional circumstances marketing authorisations and national scientific advice. https:\/\/www.gov.uk\/guidance\/conditional-marketing-authorisations-exceptional-circumstances-marketing-authorisations-and-national-scientific-advice#guidance-for-great-britain-conditional-marketing-authorisation-applications"},{"key":"e_1_3_5_30_1","unstructured":"National Medical Products Administration. (2020). Official: Emergency use of coronavirus vaccines authorized."},{"key":"e_1_3_5_31_1","unstructured":"The National Medical Products Administration. (2021 7 February). Sinovac COVID-19 vaccine granted conditional market approval in China. NMPA. Retrieved December 31 2022 from http:\/\/subsites.chinadaily.com.cn\/nmpa\/2021-02\/07\/c_588422.htm"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.07.003"},{"key":"e_1_3_5_33_1","unstructured":"Paul Ehrlich Institute. (2020). COVID-19 vaccines. https:\/\/www.pei.de\/EN\/medicinal-products\/vaccines-human\/covid-19\/covid-19-node.html"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.11124\/jbies-20-00167"},{"key":"e_1_3_5_35_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). (2020a 12 October). PMDA reveals principles on evaluation of COVID-19 vaccines https:\/\/www.pmda.go.jp\/english\/int-activities\/0008.pdf"},{"key":"e_1_3_5_36_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). (2020b 6 October). PMDA to offer free scientific advice for COVID-19 vaccines development https:\/\/www.pmda.go.jp\/english\/int-activities\/0007.pdf"},{"key":"e_1_3_5_37_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). (2021 16 February). Special approval for emergency on first COVID-19 vaccine in Japan https:\/\/www.pmda.go.jp\/english\/about-pmda\/0003.pdf"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.11.025"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1821650"},{"key":"e_1_3_5_40_1","unstructured":"Swiss Agency for Therapeutic Products (Swissmedic). (2022). Adaptation of guidance documents fast-track authorisation procedure HMV4 and temporary authorisation of human medicinal products HMV4. Retrieved December 31 2022 from https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/information\/anpassung_wl_befristete_zl.html"},{"key":"e_1_3_5_41_1","unstructured":"Swiss Agency for Therapeutic Products (Swissmedic). (2022). Current status of authorisations for combating COVID-19. https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/news\/coronavirus-covid-19\/stand-zl-bekaempfung-covid-19.html"},{"key":"e_1_3_5_42_1","volume-title":"8th Joint Conference of Taiwan and Japan","author":"Taiwan Food and Drug Administration","year":"2020","unstructured":"Taiwan Food and Drug Administration. (2020, 15 October). Accelerating COVID-19 vaccine development in Taiwan: Regulatory adjustment and clinical trial considerations. 8th Joint Conference of Taiwan and Japan."},{"key":"e_1_3_5_43_1","unstructured":"Thai Food and Drug Administration. (2021). Thai FDA notification: Conditional approval for medicinal product. Thai FDA. Retrieved December 31 2022 from https:\/\/www.fda.moph.go.th\/sites\/drug\/Shared%20Documents\/Law04-Notification-ThFDA\/FDA-20200725.pdf"},{"key":"e_1_3_5_44_1","unstructured":"Therapeutic Goods Administration. (2020). A list of ventilators permitted for supply under COVID-19 eEmergency exemption between 8 April 2020 to 31 January 2021. TGA. Retrieved December 31 2022 from https:\/\/www.tga.gov.au\/resources\/c19v"},{"key":"e_1_3_5_45_1","unstructured":"Therapeutic Goods Administration. (2021). COVID-19 vaccine provisional determinations. TGA. Retrieved December 31 2022 from https:\/\/www.tga.gov.au\/news\/news\/covid-19-vaccine-provisional-determinations"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"e_1_3_5_47_1","unstructured":"US. FDA (2021 03 Jan 2021). Coronavirus Treatment Acceleration Program (CTAP) frequently asked questions. Retrieved December 2022 from https:\/\/www.fda.gov\/drugs\/coronavirus-covid-19-drugs\/coronavirus-treatment-acceleration-program-ctap-frequently-asked-questions"},{"key":"e_1_3_5_48_1","unstructured":"U.S Food and Drug Administation. (2022). COVID-19 vaccines https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines"},{"key":"e_1_3_5_49_1","unstructured":"U.S Food and Drug Administation. (n.d.). Emergency use authorization\u2013archived information. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization-archived-information#anthrax"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.26633\/rpsp.2022.115"},{"key":"e_1_3_5_51_1","unstructured":"World Health Organization. (2022a). COVID-19 vaccines with WHO emergency use listing. WHO. Retrieved December 31 2022 from https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued"},{"key":"e_1_3_5_52_1","unstructured":"World Health Organization. (2022b). WHO coronavirus (COVID-19) dashboard. WHO. Retrieved March 31 2022 from https:\/\/covid19.who.int\/"},{"key":"e_1_3_5_53_1","unstructured":"World Health Organization. (2023). Regulatory agencies. WHO. Retrieved August 10 2023 from https:\/\/extranet.who.int\/pqweb\/medicines\/information\/regulatory-agencies"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"}],"container-title":["Journal of Pharmaceutical Policy and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20523211.2025.2520861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:20:56Z","timestamp":1765891256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20523211.2025.2520861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/20523211.2025.2520861"],"URL":"https:\/\/doi.org\/10.1080\/20523211.2025.2520861","relation":{},"ISSN":["2052-3211"],"issn-type":[{"value":"2052-3211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2520861"}}